in silico clinical trials
TRANSCRIPT
In silico trials for drug eluting BVS design,development and evaluationThe aim of InSilc is to develop an in silico clinical trial (ISCT) platform for designing, developing and assessing drug-elut-ing bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, to simulate their implanta-tion performance in the individual cardiovascular physiology.
In silico Clinical TrialsIn silico Clinical Trial refers to the use of computer modelling and simulation for evaluating the safety and efficacy of a medical device, drug or integrated treat-ment approach. Currently the evaluation of safety and efficacy is performed through in vitro, in vivo tests and clinical trials. InSilc advances the development pipeline of stents through the creation of five “what if” in silico scenarios for providing predictions of the device performance and interaction with the surrounding environment in the short and medium/long term.
+30 265 100 9006
www.insilc.eu
@InSilc.EU
InSilc
Coordinator: Prof. Dimitrios I. Fotiadis
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 777119.
Consortium
This flyer reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.
MODULESPLATFORM
3D TAWSS
Follow-up
1h
6h
3d 7d
28d1d
Deployment Module
Lumen Gain: 59%
Malapposi�on: No
0 30 60
Max Principal Strain [%]
-10 10 30
Max Principal Stress [MPa]
Provides a new approach to end users by provid-ing them all stent standard tests in silico.
Provides predictions of myocardial perfusion in the cardiac muscle.
The purpose of the model is to make an in silico prediction of the effects of the stenting proce-dure just after the stent deployment.
Predicts the micro/macro phenomena in blood and in stent restenosis after scaffold implanta-tion.
Includes three-dimensional modelling of drug release employing most novel types of anti-pro-liferation drugs.
Predicts the degradation and long-term mechanical performance of the several biore-sorbable material/device systems, through an advanced modelling framework.
Modules Validation: According to ASME V&V40 - Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices
Mechanical Modelling Module
Myocardium Perfusion Module
Deployment Module
Fluid Dynamics Module
Drug-delivery Module
Degradation Module
3D Reconstruction and Plaque Characterization ToolThe 3D Reconstruction and Plaque Characterization Tool is an integrated software tool that can be used to accurately reconstruct a part of the arteri-al tree including the lumen, the outer wall, as well as the plaques. The tool provides also the ability to accurately reconstruct the post-implantation stent configuration.
Virtual PopulationThe “virtual” population database allows the evaluation of BVS efficacy and safety and the prediction of the interaction with the surrounding environ-ment and the scaffold performance through the different virtual scenarios. The virtual database can be found at the website: cardiovascularvirtualpopulation.eu, which is open to researchers.
LogDatabase
EntityDatabase
StentRepository
Virtual CaseRepository
ResultRepository
INSILC CLOUD DATABASE STORAGE
INSILC CLOUDFILE STORAGE
INSILC CLOUD
InSilcRESTAPI
Statistics
Identify Provider
Experiment Setup Managerand Validator
WorkflowManager
WorkflowRegistry
MODULES
Log and Monitoring
Hub
Hub UIApp
AutomatedAgents
File transferManagerData Query/Provider
INSILCHUB NODE
LocalRepository
INSILCWEB APP
Experiment UI
2D Visualization
3D Visualization
AuthenticationManager
3D Reconstruction and Plaque
Characterization Tool
Local HPC Resources